Study of epidemiological aspects and hormone receptor status of meningiomas
DOI:
https://doi.org/10.18203/2320-6012.ijrms20202883Keywords:
Female, Meningioma, Progesterone receptorAbstract
Background: Meningiomas account for about a third of all central nervous system tumours worldwide. Though very common, quite less is known about its epidemiology. This study aims to establish the epidemiological parameters and hormone receptor status (Progesterone Receptor-PR) involved in the development of Meningiomas.
Methods: This observational study included 50 patients. Epidemiological parameters studied included age, sex, symptoms, history of hormone intake, smoking, recurrence, family history, history of other hormone related tumours and radiological assessment of tumour site. Surgical samples were grossed and typed according to the WHO standards. Immunohistochemical staining was done using PR to establish the role of hormonal receptors in the development of meningiomas.
Results: The mean age was 46.84±13.54 years. The ratio of male and female (Male:Female) was 1.0:2.3. 48.5% of females had history of hormonal pill intake and 28.6% had hormone related tumours, of which fibroid was most common. Amongst the sites involved cerebral convexity was most common (56%). Chi-square (χ2) test showed that there was a significant association between histological grade and PR expression of the patients (p=0.0002).
Conclusions: Positivity for hormone receptors like PR, increased intake of hormonal pills by females and association of meningioma with hormone related tumours indicates that hormonal milieu plays a significant role in the growth of meningiomasχχ. This could thus provide an insight to the pathogenesis of meningiomas. In addition, mifepristone, an anti-progestin could be a player in the medical management of meningiomas.
Metrics
References
Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-14.
Jaiswal J, Shastry AH, Ramesh A, Chickabasaviah YT, Arimappamagan A, Santosh V. Spectrum of primary intracranial tumours at a tertiary care neurological institute: A hospital based brain tumour registry. Neurol India. 2016;64:494-501.
Shah S, Gonsai RN, Makwana R. Histopathological study of meningioma in civil hospital. IJCRR. 2013 Feb 1;5(3):76.
Ikeri NZ, Anunobi CC, Bankole OB. Progesterone receptor expression and Ki-67 labelling index of meningiomas in the Lagos university teaching hospital. Niger Postgrad Med J. 2018;25:17-20.
Johnson DR, Olson JE, Vierkant RA, Hammack JE, Wang AH, Folsom AR, et al. Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study. Neuro-oncology. 2011 Sep 1;13(9):1011-9.
Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW. Relationship between tumour location, size and WHO grade in meningioma. Neurosurg Focus. 2018;44:E4.
Mehta N, Bhagwati S, Parulekar G. Meningiomas in children: A study of 18 cases. J Pediatr Neurosci. 2009;4(2):61-5.
Patil PR, Sondankar D. Clinicopathological Study of Meningioma. Int J Med Res Rev. 2016;4(4):592-01.
Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003;99:848-53.
Phillips LE, Longstreth Jr W T, Koepsell T et al. Active and Passive Cigarette Smoking and Risk of Intracranial Meningioma. Neuroepidemiology. 2005;24:117-22.
Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Family and personal medical history and risk of meningioma. J Neurosurg. 2011 Dec 1;115(6):1072-7.
Guarnaschelli JJ, Stawicki SP. Recurrent brain meningiomas. Int J Acad Med. 2017;3:Suppl S1:115-8.
Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clini Pathol. 2004 Oct 1;57(10):1033-7.
Downloads
Published
How to Cite
Issue
Section
